Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › BEAM

Beam Therapeutics

BEAM Rare disease Lead: Phase 2 6 Biotech Distilled articles ↓ 24 filings & releases ↓ Cash $213M (Sep 30, 2026) ↓ 6 verdicts ↓ 1 timing quote ↓
HematologyMetabolicRespiratory CellGene TherapyNucleic AcidProtein

Market cap $2.73B 103.5M shares (10-Q, Oct 27, 2026) × $26.41 close Nov 6, 2026

Most recent annual filing: 2026-02-24

Catalyst timeline

3 trackedQuarter catalyst calendar →
  1. BEAM-304 IND filing2026BEAM-304 IND filing, 2026, notable
  2. risto-cel BLA filingYear-End 2026risto-cel BLA filing, Year-End 2026, major
  3. risto-cel manufacturing updateas early as year-end 2026risto-cel manufacturing update, as early as year-end 2026, notable

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (6 active programs)

Technology platforms

ESCAPE

Engineered Stem Cell Antibody Paired Evasion — non-genotoxic conditioning platform combining antibody-based conditioning with multiplex gene edited HSCs; applicable ex vivo or in vivo including for sickle cell disease

Targets: CD117

Base Editing Platform

Proprietary base editing technology enabling precision genetic medicines that target a single base in the genome without double-stranded DNA breaks, using CRISPR-guided deaminase enzymes. Supports ex vivo and in vivo delivery modalities across hematology and other disease areas including sickle cell disease and beta-thalassemia.

Apellis Complement Base Editing Collaboration · Apellis Pharmaceuticals

Research collaboration using Beam's base editing technology to discover treatments for complement system-driven diseases across six programs targeting specific genes in the complement system in various organs including the eye, liver, and brain. Apellis holds exclusive option rights to license any or all programs.

Capital (as filed)

Cash
$213M cash and cash equivalents · Sep 30, 2026 (10-Q)
Short-term investments
$831M Sep 30, 2026
Operating cash flow
−$111M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$1.15B cash, runway mid-2029 per the update of Sep 8, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (6)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (6 calls)

Every verdict Biotech Distilled has published on Beam Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-04-24 Watch core Beam Therapeutics (BEAM) - Scientific Deep Dive for Risto-cel and Pipeline Products Base editing science is undeniable and the balance sheet is a fortress, but the smart move is to wait for FDA reaction to Grade 4 ALT elevations in BEAM-302 multi-dose cohort before taking a heavy position.
  2. 2026-06-18 Watch UPDATE: Beam Therapeutics (BEAM) - The Third Liver Bet Goes Clinical PKU IND clearance is a checkpoint not a re-rating event; the binding constraint of LNP hepatotoxicity in BEAM-302's multi-dose cohort remains unresolved, so the position stays on watch until hepatic safety reads out in 2H 2026.
  3. 2026-08-04 Watch UPDATE: Beam Therapeutics (BEAM) - The Pivotal Cohort Opens, The Stock Doesn't Care Pivotal cohort is dosing and the ERS late-breaker in five weeks is now a defined-event setup, but the therapeutic window of the LNP is still unproven at scale and the runway now leans on milestone-gated debt; waiting for Barcelona hepatic safety data before deploying heavily.
  4. 2026-09-08 Speculative buy speculative UPDATE: Beam Therapeutics (BEAM) - Barcelona Answers the Liver Question The single dominant failure mode — LNP hepatotoxicity — read out clean at n=29 with no Grade 4 events and 18-month durability covering the 12-month approval endpoint; remaining risks are regulatory and commercial rather than existential-biological, warranting a starter position sized for the reality that a biomarker accelerated approval is a negotiation, not a formality.
  5. 2026-10-14 Speculative buy speculative UPDATE: Beam Therapeutics (BEAM) - The Second Liver Bet Shows Its Hand A second liver program on the same LNP showed no transaminase elevation above Grade 2 and tangible efficacy at 40 mg, reinforcing the vehicle de-risking from Barcelona, though n=5 and thin follow-up keep conviction at speculative.
  6. 2026-10-28 Speculative buy speculative UPDATE: Beam Therapeutics (BEAM) - Off the Cornstarch Two of three 40 mg GSDIa patients achieved full starch independence with the liver staying quiet in a second dataset on the shared LNP, deepening the vehicle de-risking case, but n=3 at the active dose with one non-responder and serious IRRs dependent on an untested premedication fix keep the call speculative.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (1 quote from 1 filing)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (24)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 7, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

5 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)